梯瓦製藥 TEVA 深滬

等待開盤 11-12 09:30:00 美东时间

42.585

+0.185

+0.44%

華盛通

立即下載

最高42.98
今開42.71
成交量 411.57万股
最低 42.39
昨收 42.40
總市值 496.89亿
52周最高 43.34
市盈率 ^靜 35.12
換手率 0.35%
52周最低 24.34
委比 65.84%
總股本 11.67亿
歷史最高 69.088
量比 1.31
振幅 1.39%
歷史最低 6.07
每手 1
風險率 4.12%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

Teva Pharma Unveils Long-Term Growth Strategy, Targets $6B-$7B In Innovative Medicines Revenue By 2030

The Company has more than doubled revenue from innovative medicines since launching Pivot to Growth in 2023, demonstrating sustained execution and the growing strength of its high-velocity biopharma model A live webcast of the event and presentation materials will be available on Teva’s Investor Rel...

11-11 20:32
梯瓦制药收涨0.84%，成交额1.97亿美元

11月10日，梯瓦制药（TEVA）收涨0.84%，报42.97美元，成交额1.97亿美元，市值501.39亿美元。行情数据 • 开盘价：43.01美元 • 最...

11-10 05:37
美股大行评级 | 大摩上调AMD目标价至725美元；安进、多邻国绩后获华尔街大行看多

今日重点评级关注：康托·菲茨杰拉德：维持Supernus"超配"评级，目标价从67美元升至87美元；丰业银行：维持Atlas Energy Solutions"跑赢大市"评级，目标价从17美元升至18美元

11-05 14:06
MindWalk Holdings Inks Agreement With Teva Pharmaceuticals Australia To Deploy ReefIQ

MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced a multi-year agreement with Teva Pharmaceuticals Australia Pty Ltd ("Teva Australia") to deploy ReefIQ™, MindWalk’s HYFT®-powered biological context layer with specified LensAI™ analytical capabilities, in ...

11-04 21:12
Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

Vaxcyte announced positive topline data from the OPUS-1 pivotal Phase 3 trial for VAX-31, meeting all primary endpoints and demonstrating a favorable safety profile. The company expects to report results from OPUS-2 and OPUS-3 trials in early 2027, supporting a planned BLA submission in early 2028. VAX-31 infant data and VAX-A1 Phase 1 results are anticipated in 2027. Vaxcyte completed $1.1 billion in net proceeds from October 2026 offerings, str...

11-04 21:05
财报速睇 | 梯瓦制药 2026财年Q3营收43.95亿美元，同比下降1.9%；归母净利润2.33亿美元，同比下滑46.2%

华盛资讯11月4日讯，梯瓦制药公布2026财年Q3业绩，公司Q3营收43.95亿美元，同比下降1.9%，归母净利润2.33亿美元，同比下滑46.2%。

11-04 08:46
Teva CEO Sees Strong Austedo Demand Cushioning Medicare Pricing Blow in 2027

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) stock rose Tuesday after the Israeli drugmaker reported better-than-expected third-quarter earnings and raised its full-year outlook. The company reported adjusted earnings of 86 cents per share, beating the analyst estimate of 73 cents. Revenue fell 2...

11-04 02:15
美股异动 | 三季度创新药营收同比增长33% 梯瓦制药(TEVA.US)涨逾4%

周二，梯瓦制药(TEVA.US)涨逾4%，报42.65美元，股价创历史新高。消息面上，梯瓦制药公布2026年第三季度财报，公司非GAAP每股收益0.86美元，超...

11-03 23:09
财报速睇 | 梯瓦制药 2026财年Q3营收43.95亿美元，同比下降1.9%；归母净利润2.33亿美元，同比下滑46.2%

华盛资讯11月3日讯，梯瓦制药公布2026财年Q3业绩，公司Q3营收43.95亿美元，同比下降1.9%，归母净利润2.33亿美元，同比下滑46.2%。

11-03 23:05
梯瓦制药（TEVA）Q3非GAAP每股收益0.86美元创新药合计营收11亿美元同比增33%

金吾资讯

11-03 20:59

派息除權日	每股總股息	派息日期
2017-11-28	0.09	2017-12-12
2017-11-27	0.07	2017-12-12
2017-08-25	0.07	2017-09-14
2017-06-01	0.29	2017-06-22
2017-02-28	0.29	2017-03-20
2016-12-01	0.29	2016-12-20
2016-08-18	0.29	2016-09-08
2016-05-20	0.29	2016-06-07
2016-02-25	0.29	2016-03-14
2015-11-13	0.29	2015-12-03
2015-08-18	0.29	2015-09-03
2015-05-15	0.29	2015-06-04
2015-02-17	0.29	2015-03-03
2014-11-13	0.27	2014-12-02
2014-08-19	0.29	2014-09-04
2014-05-16	0.30	2014-06-02
2014-02-20	0.29	2014-03-10
2013-11-18	0.28	2013-12-03
2013-08-16	0.27	2013-09-03
2013-05-16	0.27	2013-06-03
2013-02-19	0.27	2013-03-07
2012-11-13	0.20	2012-12-03
2012-08-13	0.21	2012-09-04
2012-05-17	0.20	2012-06-04
2012-02-23	0.20	2012-03-15
2011-11-09	0.17	2011-12-07
2011-08-04	0.20	2011-08-25
2011-05-19	0.20	2011-06-07
2011-02-10	0.22	2011-03-07
2010-11-08	0.17	2010-12-06
2010-08-02	0.17	2010-08-26
2010-05-10	0.16	2010-06-04
2010-02-19	0.16	2010-03-17
2009-11-06	0.13	2009-12-04
2009-08-03	0.12	2009-08-27
2009-05-08	0.12	2009-06-03
2009-02-23	0.11	2009-03-19
2008-11-07	0.09	2008-12-05
2008-08-01	0.10	2008-08-27
2008-05-13	0.11	2008-06-05
2008-02-15	0.10	2008-03-13
2007-11-02	0.08	2007-11-28
2007-08-10	0.08	2007-09-06
2007-05-10	0.08	2007-06-05
2007-02-16	0.08	2007-03-15
2006-11-10	0.07	2006-12-06
2006-08-11	0.06	2006-09-08
2006-05-12	0.06	2006-06-07
2006-03-06	0.06	2006-03-30
2005-11-10	0.05	2005-12-07
2005-08-11	0.05	2005-09-07
2005-05-05	0.06	2005-06-01
2005-02-17	0.06	2005-03-17
2004-11-09	0.04	2004-12-06
2004-08-09	0.04	2004-09-07
2004-05-10	0.15	2004-06-07
2004-02-20	0.08	2004-03-22
2003-11-13	0.06	2003-12-12
2003-08-08	0.06	2003-09-08
2003-05-08	0.06	2003-06-06
2003-02-24	0.05	2003-03-24
2002-11-07	0.07	2002-12-06
2002-08-19	0.07	2002-09-16
2002-05-20	0.07	2002-06-17
2002-02-15	0.08	2002-03-18
2001-11-16	0.05	2001-12-17
2001-08-20	0.05	2001-09-17
2001-05-17	0.05	2001-06-15
2001-03-08	0.05	2001-04-06
2000-11-16	0.04	2000-12-15
2000-08-24	0.04	2000-09-21
2000-05-19	0.04	2000-06-19
2000-02-17	0.08	2000-03-27
1999-11-04	0.05	1999-11-30
1999-08-18	0.05	1999-09-13
1999-05-21	0.05	1999-06-15
1999-03-08	0.05	1999-03-30
1998-11-20	0.05	1998-12-11
1998-08-21	0.06	1998-09-11
1998-05-21	0.06	1998-06-22
1998-03-12	0.06	1998-03-31
1997-11-20	0.07	1997-12-09
1997-08-25	0.07	1997-09-11
1997-05-23	0.07	1997-06-12
1997-03-07	0.07	1997-03-26
1996-11-20	0.05	1996-12-09
1996-08-26	0.05	1996-09-12
1996-05-23	0.05	1996-06-12
1996-03-07	0.05	1996-03-26
1995-11-20	0.05	1995-12-07
1995-08-14	0.05	1995-08-30
1995-05-17	0.05	1995-06-07
1995-03-07	0.05	1995-04-04
1994-11-15	0.05	1994-12-13
1994-08-09	0.05	1994-09-12
1994-05-18	0.05	1994-06-21
1994-03-08	0.05	1994-04-05
1993-11-17	0.04	1994-01-03
1993-08-17	0.04	1993-09-14
1993-05-18	0.03	1993-06-21
1993-04-07	0.06	1993-05-05
1992-11-17	0.04	1992-12-21
1992-08-18	0.04	1992-09-21
1991-11-20	0.04	1991-12-19
1991-08-20	0.04	1991-09-19
1991-05-19	0.04	1991-07-19
1991-03-05	0.04	1991-03-28
1990-11-20	0.04	1990-12-20
1990-08-16	0.04	1990-09-17
1989-05-21	0.04	1989-06-18
1988-12-06	0.04	1988-12-30
1988-09-07	0.04	1988-10-05
1988-06-09	0.03	1988-07-19
1988-04-11	0.03	1988-05-15
1988-02-08	0.03	1988-03-10
1987-10-23	0.03	1987-11-19
1987-07-08	0.04	1987-08-04
1987-06-21	0.03	1987-07-13
1987-02-23	0.03	1987-03-26
1985-09-23	0.02	1985-10-21
1985-06-17	0.02	1985-07-15
1984-01-27	0.02	1984-02-29
1982-08-16	0.40	1982-09-13
1982-08-10	0.06	1982-09-13

公司名稱	梯瓦制药
行業分類	制药
業務描述	Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

梯瓦製藥 TEVA 深 滬

42.585

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

梯瓦製藥 TEVA 深滬